Telix Pharmaceuticals Ltd
Officers & Directors
Darren Smith has served as Group Chief Financial Officer since August 2022. He has over 20 years of experience in finance and management and holds an MBA from the University of New South Wales and a Bachelor of Business from Western Sydney University. David Cade has been Group Chief Medical Officer since January 2024. He was previously CEO of Asia Pacific operations and Chief Medical Officer at Sirtex Medical Limited and Cochlear Limited. He holds an MBBS from Monash Medical School and an MBA from Melbourne Business School and ESADE Business and Law School Barcelona. Darren Patti has been Group Chief Operating Officer since March 2024. He has over 20 years of experience in radiopharmaceutical and device manufacturing and holds a Pharm.D. from the University of Illinois at Chicago and a Bachelor of Arts from Southern Illinois University at Carbondale. Kevin Richardson is Chief Executive Officer of Telix Precision Medicine, with over 25 years in healthcare. He was previously COO of UroShape Medical and has experience at Sirtex Medical Ltd. Mary Jessel is Group Chief of Clinical Affairs, with over 15 years in pharmaceutical and biotechnology. She holds a PhD in Neuroscience from the University of Michigan and an MBA from Portland State University. Richard Valeix is Chief Executive Officer of Telix Therapeutics, with more than 20 years of pharmaceutical industry experience, including senior executive roles in radiopharmaceuticals.
Telix Pharmaceuticals Ltd currently has 1120 employees.
|
